Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

(2017) Pablo A Fraile-Ribot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

(2016) Deanna J. Buehrle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa

(2016) Stephen B. Vickery et al.   PHARMACOTHERAPY

The increasing threat of Pseudomonas aeruginosa high-risk clones

(2015) Antonio Oliver et al.   DRUG RESISTANCE UPDATES

Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania

(2015) G. Mikucionyte et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model

(2014) Brian D. VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems

(2013) Oren Zusman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

(2013) H. W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities

(2012) Bartolomé Moyá et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones

(2012) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model

(2011) Phillip J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Activity of a New Cephalosporin, CXA-101 (FR264205), against  -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differing Effects of Combination Chemotherapy with Meropenem and Tobramycin on Cell Kill and Suppression of Resistance of Wild-Type Pseudomonas aeruginosa PAO1 and Its Isogenic MexAB Efflux Pump-Overexpressed Mutant

(2009) G. L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections

(2009) M. Montero et al.   INFECTION